文献速递甲状腺疾病

贝塞斯达III和IV类甲状腺结节在Afirma GSC或Thyroseq v3分子检测后非手术管理

Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究前瞻性随访单中心随机临床试验中176个贝塞斯达III/IV类甲状腺结节,分子检测阴性或良性者中162个(92%)接受主动监测,中位随访34个月,总体假阴性率为0.6%,结论支持当前分子检测高敏感性及其排除恶性作用。

要点

  • 176个分子检测阴性或良性的贝塞斯达III/IV类结节中,162个(92%)接受非手术主动监测。
  • 中位监测34个月(范围12-60个月),监测中切除15个结节,发现1例恶性,总体假阴性率0.6%。
  • 该恶性为2.7 cm微小浸润性Hurthle细胞癌,最初Thyroseq v3检测阴性,因超声下增大而延迟切除。

核心结论

  • 大多数分子检测阴性或良性的贝塞斯达III/IV类甲状腺结节在3年随访中保持稳定。
  • 这些发现支持当前分子检测的高敏感性及其在排除不确定性甲状腺结节恶性中的作用。

研究设计与样本

  • 单中心随机临床试验的前瞻性随访,比较Afirma GSC与Thyroseq v3在不确定性甲状腺结节诊断中的表现。
  • 连续纳入2017年8月至2019年11月在加州大学洛杉矶分校(UCLA)健康系统接受甲状腺活检且细胞学为贝塞斯达III和IV类的参与者。

主要发现

  • 176个分子检测阴性或良性的不确定性结节中,14个(8%)立即切除,手术病理未发现恶性。
  • 162个(92%)结节接受主动监测的非手术管理,中位监测34个月(范围12-60个月),44例患者失访。
  • 监测期间切除15个结节,发现1例恶性,总体假阴性率0.6%。
  • 该恶性为2.7 cm微小浸润性Hurthle细胞癌,最初Thyroseq v3检测阴性,因监测中超声下增大而延迟切除。

局限性

  • 44例患者失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Molecular testing has improved risk stratification and increased nonoperative management for patients with indeterminate thyroid nodules, but data on the long-term outcomes of current molecular tests Afirma Gene Sequencing Classifier (GSC) and Thyroseq v3 are limited. OBJECTIVE: To determine the rate of delayed operation and the false negative rate of the Afirma GSC and Thyroseq v3 in Bethesda III and IV thyroid nodules. METHODS: Prospective follow-up of a single center, randomized, clinical trial comparing the performance of Afirma GSC and Thyroseq v3 in the diagnosis of indeterminate thyroid nodules at the University of California, Los Angeles (UCLA). Consecutive participants who underwent thyroid biopsy in the UCLA health system with Bethesda III and IV cytology from August 2017 to November 2019. The main outcome measure was false negative rate of molecular testing. RESULTS: Of 176 indeterminate nodules with negative or benign molecular test results, 14 (8%) nodules underwent immediate resection, with no malignancies found on surgical pathology. Nonoperative management with active surveillance was pursued for 162 (92%) nodules with benign or negative test results. The median surveillance was 34 months (range 12-60 months), and 44 patients were lost to follow-up. Of 15 nodules resected during surveillance, 1 malignancy was found (overall false negative rate of 0.6%). This was a 2.7 cm minimally invasive Hurthle cell carcinoma that initially tested negative with Thyroseq v3 and underwent delayed resection due to sonographic growth during surveillance. CONCLUSIONS: The majority of Bethesda III/IV thyroid nodules with negative or benign molecular test results are stable over 3 years of follow-up. These findings support the high sensitivity of current molecular tests and their role in ruling out malignancy in indeterminate thyroid nodules.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kim NE, Raghunathan RS, Hughes EG, et al. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3. J Clin Endocrinol Metab. 2023. PMID: 36995878. doi:10.1210/clinem/dgad181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。